禾元生物 - Financials

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	25.2M	24.3M	13.4M	25.5M	21.6M
Revenue Growth %	3.9%	81.1%	-47.5%	18.3%	--
Total Revenue	25.2M	24.3M	13.4M	25.5M	21.6M
Cost Of Revenue	9.2M	11.1M	4.9M	9.9M	6.2M
+Gross Profit	16.0M	13.2M	8.5M	15.6M	15.4M
Gross Margin %	63.5%	54.3%	63.6%	61.2%	71.3%
Total Operating Cost	195.0M	227.0M	162.0M	155.0M	85.5M
Selling Expenses	4.5M	4.9M	2.4M	2.0M	3.4M
Admin Expenses	58.9M	54.0M	56.6M	69.4M	29.5M
Rd Expenses	117.0M	159.0M	110.0M	75.2M	45.1M
Finance Expenses	2.9M	-4.9M	-14.8M	-2.1M	1.2M
+Operating Income	-151.0M	-187.0M	-142.0M	-134.0M	-53.4M
Operating Margin %	-598.8%	-770.7%	-1059.7%	-525.1%	-247.4%
Non Operating Income	--	30,000	--	--	--
Non Operating Expenses	--	500.00	1.5M	--	--
Asset Disposal Income	-1.3M	1.0M	329,000	-11.3M	2.1M
Asset Impairment Loss	477,400	1.1M	1.3M	400.00	64,300
Other Income	19.3M	14.8M	5.9M	6.4M	8.5M
Income Before Tax	-151.0M	-187.0M	-144.0M	-134.0M	-53.4M
Income Tax	--	--	--	--	--
+Net Income	-151.0M	-187.0M	-144.0M	-134.0M	-53.4M
Net Margin %	-598.8%	-770.7%	-1074.7%	-525.1%	-247.4%
Net Income Attributable	-151.0M	-187.0M	-144.0M	-134.0M	-53.4M
Eps Basic	-0.56	-0.70	-0.55	-0.62	-1.07
Eps Diluted	-0.56	-0.70	-0.55	-0.62	-1.07

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	160.0M	236.0M	388.0M	243.0M	151.0M
Accounts Receivable	144,400	202,200	89,900	21,500	20,900
Notes And Accounts Receivable	144,400	202,200	89,900	21,500	20,900
Prepayments	5.0M	3.7M	7.9M	4.8M	2.7M
Inventory	50.0M	35.7M	25.7M	12.5M	13.4M
Total Current Assets	237.0M	289.0M	448.0M	283.0M	170.0M
Fixed Assets	--	593.0M	170.0M	--	41.0M
Fixed Assets Total	574.0M	593.0M	170.0M	7.7M	41.0M
Construction In Progress	--	9.7M	409.0M	--	2.2M
Construction In Progress Total	134.0M	9.7M	409.0M	200.0M	2.2M
Intangible Assets	87.4M	66.2M	68.1M	24.5M	26.2M
Long Term Deferred Expenses	3.6M	74,700	--	--	--
Total Non Current Assets	824.0M	674.0M	654.0M	310.0M	69.6M
Total Assets	1.1B	962.0M	1.1B	593.0M	240.0M
Short Term Borrowings	10.0M	--	--	--	100,200
Accounts Payable	176.0M	106.0M	170.0M	122.0M	5.6M
Advance Receipts	--	--	--	--	--
Contract Liabilities	2.4M	1.9M	1.1M	546,500	5.1M
Total Current Liabilities	233.0M	121.0M	191.0M	132.0M	17.9M
Long Term Borrowings	184.0M	90.1M	13.1M	--	9.6M
Total Non Current Liabilities	228.0M	110.0M	16.6M	2.2M	13.5M
Total Liabilities	460.0M	231.0M	207.0M	134.0M	31.5M
Paid In Capital	268.0M	268.0M	268.0M	239.0M	55.9M
Capital Reserve	1.2B	1.2B	1.1B	590.0M	388.0M
Retained Earnings	-851.0M	-700.0M	-513.0M	-369.0M	-235.0M
Equity Attributable	601.0M	732.0M	895.0M	459.0M	208.0M
Total Equity	601.0M	732.0M	895.0M	459.0M	208.0M

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	28.3M	30.4M	15.1M	23.0M	25.8M
Tax Refunds Received	3.4M	29.8M	44.6M	2.1M	571,100
Total Operating Cash Inflow	98.5M	96.1M	87.3M	36.0M	35.1M
Cash Paid For Goods	69.4M	152.0M	82.0M	44.7M	29.9M
Cash Paid To Employees	43.3M	40.2M	34.4M	25.7M	16.0M
Taxes Paid	1.8M	1.9M	445,300	332,800	127,600
Total Operating Cash Outflow	152.0M	219.0M	154.0M	124.0M	70.3M
Operating Cash Flow	-53.5M	-123.0M	-66.4M	-88.0M	-35.2M
Total Investing Cash Inflow	40.5M	--	680,800	--	--
Total Investing Cash Outflow	167.0M	102.0M	358.0M	175.0M	1.7M
Investing Cash Flow	-126.0M	-102.0M	-358.0M	-175.0M	-1.7M
Cash From Borrowings	134.0M	78.0M	30.4M	9.9M	12.6M
Dividends And Interest Paid	4.6M	1.2M	740,100	656,300	1.1M
Debt Repayments	23.5M	1.0M	16.3M	19.9M	14.2M
Total Financing Cash Inflow	134.0M	78.0M	587.0M	377.0M	189.0M
Total Financing Cash Outflow	29.3M	5.3M	18.6M	20.9M	15.3M
Financing Cash Flow	104.0M	72.6M	568.0M	356.0M	174.0M
Net Change In Cash	-75.6M	-152.0M	144.0M	92.8M	136.0M
Ending Cash Balance	160.0M	236.0M	388.0M	243.0M	151.0M
Capex	167.0M	102.0M	358.0M	175.0M	1.7M